Bellevue Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Bellevue Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-138	Closed	-$1.21K	–	466
2023 Q4	$1.21K	Buy	138 +45	+48%	+$369	﹤0.01%	445
2023 Q3	$1.07K	Hold	93	–	–	﹤0.01%	446
2023 Q2	$2.35K	Hold	93	–	–	﹤0.01%	388
2023 Q1	$3K	Buy	93 +17	+22%	+$530	﹤0.01%	370
2022 Q4	$1.38K	Hold	76	–	–	﹤0.01%	447
2022 Q3	$2K	Hold	76	–	–	﹤0.01%	448
2022 Q2	$1K	Hold	76	–	–	﹤0.01%	494
2022 Q1	$1K	Sell	76 -16	-17%	-$243	﹤0.01%	529
2021 Q4	$2K	Sell	92 -7	-7%	-$117	﹤0.01%	526
2021 Q3	$3K	Hold	99	–	–	﹤0.01%	486
2021 Q2	$3K	Sell	99 -9	-8%	-$260	﹤0.01%	484
2021 Q1	$3K	Sell	108 -15	-12%	-$415	﹤0.01%	544
2020 Q4	$3K	Buy	123 +56	+84%	+$1.45K	﹤0.01%	558
2020 Q3	$2K	Hold	67	–	–	﹤0.01%	579
2020 Q2	$2K	Hold	67	–	–	﹤0.01%	573
2020 Q1	$1K	Buy	67 +34	+103%	+$703	﹤0.01%	597
2019 Q4	$1K	Buy	+33	New	+$512	﹤0.01%	531

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Asset Management's RVNC Position: Q1 2024 in Review

Bellevue Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2024, closing a stake of 138 shares — an estimated $1.21K sold.

Bellevue Asset Management first reported a position in RVNC in Q4 2019 and held it in 17 quarters. The position peaked at $3K in Q3 2021. 188 funds tracked by Wall St. Rank hold RVNC as of Q1 2024.

Bellevue Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2024 after selling out during the quarter.
Bellevue Asset Management sold 138 Revance Therapeutics, Inc. shares in Q1 2024, an estimated $1.21K.
Bellevue Asset Management first reported a position in Revance Therapeutics, Inc. in Q4 2019 and held it in 17 quarters.
Bellevue Asset Management's Revance Therapeutics, Inc. position peaked at $3K in Q3 2021.
188 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2024.

Based on Bellevue Asset Management's 13F filing for Q1 2024, filed 26 Apr 2024.